Binding of a Fatty Acid-Functionalized Anderson-Type Polyoxometalate to Human Serum Albumin.
Bijelic, A., Dobrov, A., Roller, A., Rompel, A.(2020) Inorg Chem 59: 5243-5246
- PubMed: 32255347 
- DOI: https://doi.org/10.1021/acs.inorgchem.9b03407
- Primary Citation of Related Structures:  
6XV0 - PubMed Abstract: 
The Anderson-type hexamolybdoaluminate functionalized with lauric acid (LA), (TBA) 3 [Al(OH) 3 Mo 6 O 18 {(OCH 2 ) 3 CNHCOC 11 H 23 }]·9H 2 O (TBA-AlMo 6 -LA, where TBA = tetrabutylammonium), was prepared via two synthetic routes and characterized by thermogravimetric and elemental analyses, mass spectrometry, IR and 1 H NMR spectroscopy, and powder and single-crystal X-ray diffraction. The interaction of TBA-AlMo 6 -LA with human serum albumin (HSA) was investigated via fluorescence and circular dichroism spectroscopy. The results revealed that TBA-AlMo 6 -LA binds strongly to HSA (63% quenching at an HSA/TBA-AlMo 6 -LA ratio of 1:1), exhibiting static quenching. In contrast to TBA-AlMo 6 -LA, the nonfunctionalized polyoxometalate, Na 3 (H 2 O) 6 [Al(OH) 6 Mo 6 O 18 ]·2H 2 O (AlMo 6 ), showed weak binding toward HSA (22% quenching at a HSA/AlMo 6 ratio of 1:25). HSA binding was confirmed by X-ray structure analysis of the HSA-Myr-AlMo 6 -LA complex (Myr = myristate). These results provide a promising lead for the design of novel polyoxometalate-based hybrids that are able to exploit HSA as a delivery vehicle to improve their pharmacokinetics and bioactivity.
Organizational Affiliation: 
Fakultät für Chemie, Institut für Biophysikalische Chemie, Universität Wien, Althanstraße 14, 1090 Wien, Austria.